Less necessity of adjuvant S-1 treatment in non-monarchE-eligible patients.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.6006
Abstract: BACKGROUND In monarchE and Postoperative Therapy with Endocrine and TS-1 (POTENT) trials, abemaciclib and S-1 have, respectively, shown to be effective as adjuvant therapies for luminal breast cancer (BC), although whether patients who meet the… read more here.
Keywords: eligible patients; potent; monarche eligible; non eligible ... See more keywords
Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.17_suppl.lba507
Abstract: LBA507 Background: In monarchE (NCT03155997), 2 years of adjuvant abemaciclib + ET resulted in sustained improvement in invasive disease-free survival (IDFS; HR=0.680, 7.6% absolute benefit at 5 years) in patients (pts) with HR+, HER2-, node-positive,… read more here.
Keywords: therapy; ctdna detection; risk; monarche ... See more keywords
Abemaciclib Therapy Using the MonarchE Criteria Results in Large Numbers of Excess Axillary Node Clearances—Time to Pause and Reflect?
Sign Up to like & getrecommendations! Published in 2024 at "Cancers"
DOI: 10.3390/cancers16173072
Abstract: Simple Summary Abemaciclib is an important addition to the care of women with hormone receptor-positive breast cancer. To qualify for abemaciclib treatment, some women are advised to undergo axillary node clearance surgery as finding more… read more here.
Keywords: abemaciclib; canc; axillary node; monarche ... See more keywords